TFF3 facilitates dormancy of anti-estrogen treated ER+ mammary carcinoma
Tumor dormancy is a substantial clinical obstacle in treatment of estrogen receptor positive mammary carcinoma (ER+MC), contributing to drug resist…
Category: Drug development